Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is well positioned for success in the metabolic disease treatment space with its innovative approach and promising lead product, Revita. The encouraging clinical trial results and potential FDA approval in 2026 provide a strong foundation for the company's future growth. The efficient review process for their device and sufficient funding until 2027 further support the positive outlook for Fractyl Health. However, it is important to consider the standard industry risks that could impact the company's success.

Bears say

Fractyl Health is in a strong position with its lead product candidate, Revita, which holds FDA Breakthrough Device Designation and is currently under review in a pivotal trial. With the recently announced RAPID coverage pathway potentially shortening the timeline for Medicare coverage, Revita's development strategy appears to align well. Early data shows a significant correlation between procedure ablation length and weight maintenance, providing a strong "drug-like" response. However, long-term data is still needed to fully assess the potential for weight regain after discontinuation of GLP-1 treatment.

GUTS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GUTS has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.